Loading
Chronic Myeloid Leukemia Treatments / Lung Cancer Treatments and Mutations / Colorectal Cancer Treatments and Studies · Journal article
BMC Cancer · September 7, 2026
Encouraging direction, but not yet definitive.
This retrospective analysis of 452 Chinese NSCLC patients describes the distribution of four structural EGFR mutation subgroups and reports that patients with compound or co-occurring EGFR mutations exhibit worse TKI response than those with single classical mutations. The finding is statistically significant but derived from small subgroup sizes and surrogate clinical response, not survival or progression-free survival.
Retrospective single-center cohort study. Chinese patients diagnosed with NSCLC at a single center; all eligible patients with sufficient samples for NGS testing were enrolled; no explicit exclusion criteria stated.. Intervention: EGFR tyrosine kinase inhibitor (TKI) therapy; specific TKI agents not detailed.. Compared with: Patients with single classical EGFR mutations served as reference for comparison of clinical response in compound and co-mutation groups.. n = 452. Single center in China.
81.64% of 452 NSCLC patients harbored at least one gene alteration; EGFR was most frequent at 53% Among EGFR-mutant patients, 80.33% were classical-like, 6.69% were T790M-like, 3.35% were Ex20ins-L, and 4.60% were PACC Patients with compound EGFR mutations (n=28) had worse clinical response to first-line TKIs compared with single classical mutations (P = 0.022)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians treating Chinese NSCLC patients should recognize that compound and co-occurring EGFR mutations predict reduced TKI efficacy compared to single classical mutations, which may inform treatment selection and monitoring. However, the clinical response endpoint used is not defined in detail, and progression-free survival or overall survival data are not provided, so the magnitude of clinical benefit or harm remains uncertain.
A single-center retrospective cohort study with clear findings on EGFR mutation subtypes and TKI sensitivity in a defined population, but limited by retrospective design, lack of survival or clinical outcome detail, and modest sample sizes for the key comparison groups.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians treating Chinese NSCLC patients should recognize that compound and co-occurring EGFR mutations predict reduced TKI efficacy compared to single classical mutations, which may inform treatment selection and monitoring. However, the clinical response endpoint used is not defined in detail, and progression-free survival or overall survival data are not provided, so the magnitude of clinical benefit or harm remains uncertain.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Epidermal growth factor receptor( EGFR )mutations have been classified into four distinct subgroups based on the characteristics of the kinase domain and their sensitivity to tyrosine kinase inhibitors (TKIs).However, literature regarding the distribution and biological features of these structural subtypes among Chinese patients with non-small cell lung cancer (NSCLC) remains limited.This retrospective study aims to further investigate the distribution characteristics of EGFR mutations and the sensitivity of complex EGFR mutations to TKIs in Chinese patients. A total of 452 patients diagnosed with NSCLC were enrolled in this study. All samples were screened for EGFR, KRAS, ALK, ROS1, MET, ERBB2, RET, BRAF, and NTRK1/2/3 mutations using next-generation sequencing (NGS). EGFR mutations were systematically categorized into four subgroups based on the structural classification method. Drug sensitivities to various EGFR- TKIs were analyzed separately in 28 patients with compound EGFR mutations and 39 patients with EGFR co-mutations. Additionally, the correlation between driver gene mutations and clinicopathological characteristics was also evaluated. Approximately 81.64% of patients with NSCLC harbored at least one gene alteration, the three most frequent genomic alterations were EGFR (53%), KRAS (13%), and ALK (11%). Among EGFR -mutant patients, 80.33% were classical-like, 6.69% were T790M-like, 3.35% were Ex20ins-L, and 4.60% were PACC. Predominantly, L858R and exon 19 deletions(19del)accounted for 50% and 46.88% of classical-like mutations, respectively. Compared with patients harboring a single classical EGFR mutation, those with compound EGFR mutations had worse clinical response to first-line TKIs ( P = 0.022), and patients with co-occurring EGFR mutations also exhibited poorer sensitivity to TKIs ( P = 0.045). Statistical analysis indicated that the EGFR mutation rate was significantly higher in females and in patients with adenocarcinoma. ALK mutations were significantly positively correlated with tumor site and lymph node metastasis, and male patients were more likely to harbor RET mutations. EGFR mutations were predominantly of the classical-like type in Chinese patients with NSCLC. Our results also confirm that EGFR compound mutations and co-mutations reduce the efficacy of various TKIs. These findings will facilitate drug development and personalized targeted therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.